207 related articles for article (PubMed ID: 35226736)
21. Hsp90 inhibition destabilizes Ezh2 protein in alloreactive T cells and reduces graft-versus-host disease in mice.
Huang Q; He S; Tian Y; Gu Y; Chen P; Li C; Huang J; Liu Y; Yu H; Jin M; Hu S; Tong Q; Ma A; Jin J; Hexner E; Fung H; Reshef R; Zhang Y; Zhang Y
Blood; 2017 May; 129(20):2737-2748. PubMed ID: 28246193
[TBL] [Abstract][Full Text] [Related]
22. Inert Gas Washout in Bronchiolitis Obliterans Following Hematopoietic Cell Transplantation.
Nyilas S; Baumeler L; Tamm M; Halter JP; Savic S; Korten I; Meyer A; Singer F; Passweg JR; Latzin P; Stolz D
Chest; 2018 Jul; 154(1):157-168. PubMed ID: 29275133
[TBL] [Abstract][Full Text] [Related]
23. EZH2 Cooperates with BRD4-NUT to Drive NUT Carcinoma Growth by Silencing Key Tumor Suppressor Genes.
Huang Y; Durall RT; Luong NM; Hertzler HJ; Huang J; Gokhale PC; Leeper BA; Persky NS; Root DE; Anekal PV; Montero Llopis PDLM; David CN; Kutok JL; Raimondi A; Saluja K; Luo J; Zahnow CA; Adane B; Stegmaier K; Hawkins CE; Ponne C; Le Q; Shapiro GI; Lemieux ME; Eagen KP; French CA
Cancer Res; 2023 Dec; 83(23):3956-3973. PubMed ID: 37747726
[TBL] [Abstract][Full Text] [Related]
24. Targeting Sirt-1 controls GVHD by inhibiting T-cell allo-response and promoting Treg stability in mice.
Daenthanasanmak A; Iamsawat S; Chakraborty P; Nguyen HD; Bastian D; Liu C; Mehrotra S; Yu XZ
Blood; 2019 Jan; 133(3):266-279. PubMed ID: 30514750
[TBL] [Abstract][Full Text] [Related]
25. Extrafollicular CD4
Deng R; Hurtz C; Song Q; Yue C; Xiao G; Yu H; Wu X; Muschen M; Forman S; Martin PJ; Zeng D
Nat Commun; 2017 Oct; 8(1):978. PubMed ID: 29042531
[TBL] [Abstract][Full Text] [Related]
26. EZH2 enables germinal centre formation through epigenetic silencing of CDKN1A and an Rb-E2F1 feedback loop.
Béguelin W; Rivas MA; Calvo Fernández MT; Teater M; Purwada A; Redmond D; Shen H; Challman MF; Elemento O; Singh A; Melnick AM
Nat Commun; 2017 Oct; 8(1):877. PubMed ID: 29026085
[TBL] [Abstract][Full Text] [Related]
27. The histone methyltransferase Ezh2 is a crucial epigenetic regulator of allogeneic T-cell responses mediating graft-versus-host disease.
He S; Xie F; Liu Y; Tong Q; Mochizuki K; Lapinski PE; Mani RS; Reddy P; Mochizuki I; Chinnaiyan AM; Mineishi S; King PD; Zhang Y
Blood; 2013 Dec; 122(25):4119-28. PubMed ID: 24141370
[TBL] [Abstract][Full Text] [Related]
28. Trafficking between clonally related peripheral T-helper cells and tissue-resident T-helper cells in chronic GVHD.
Kong X; Wu X; Wang B; Zeng D; Cassady K; Nasri U; Zheng M; Wu A; Qin H; Tsai W; Salhotra A; Nakamura R; Martin PJ; Zeng D
Blood; 2022 Dec; 140(25):2740-2753. PubMed ID: 36084473
[TBL] [Abstract][Full Text] [Related]
29. B cells in chronic graft-versus-host disease.
McManigle W; Youssef A; Sarantopoulos S
Hum Immunol; 2019 Jun; 80(6):393-399. PubMed ID: 30849450
[TBL] [Abstract][Full Text] [Related]
30. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation.
Béguelin W; Popovic R; Teater M; Jiang Y; Bunting KL; Rosen M; Shen H; Yang SN; Wang L; Ezponda T; Martinez-Garcia E; Zhang H; Zheng Y; Verma SK; McCabe MT; Ott HM; Van Aller GS; Kruger RG; Liu Y; McHugh CF; Scott DW; Chung YR; Kelleher N; Shaknovich R; Creasy CL; Gascoyne RD; Wong KK; Cerchietti L; Levine RL; Abdel-Wahab O; Licht JD; Elemento O; Melnick AM
Cancer Cell; 2013 May; 23(5):677-92. PubMed ID: 23680150
[TBL] [Abstract][Full Text] [Related]
31. CSF-1-dependant donor-derived macrophages mediate chronic graft-versus-host disease.
Alexander KA; Flynn R; Lineburg KE; Kuns RD; Teal BE; Olver SD; Lor M; Raffelt NC; Koyama M; Leveque L; Le Texier L; Melino M; Markey KA; Varelias A; Engwerda C; Serody JS; Janela B; Ginhoux F; Clouston AD; Blazar BR; Hill GR; MacDonald KP
J Clin Invest; 2014 Oct; 124(10):4266-80. PubMed ID: 25157821
[TBL] [Abstract][Full Text] [Related]
32. Invariant natural killer T cells ameliorate murine chronic GVHD by expanding donor regulatory T cells.
Du J; Paz K; Thangavelu G; Schneidawind D; Baker J; Flynn R; Duramad O; Feser C; Panoskaltsis-Mortari A; Negrin RS; Blazar BR
Blood; 2017 Jun; 129(23):3121-3125. PubMed ID: 28416503
[TBL] [Abstract][Full Text] [Related]
33. Murine chronic graft-versus-host disease proteome profiling discovers CCL15 as a novel biomarker in patients.
Du J; Flynn R; Paz K; Ren HG; Ogata Y; Zhang Q; Gafken PR; Storer BE; Roy NH; Burkhardt JK; Mathews W; Tolar J; Lee SJ; Blazar BR; Paczesny S
Blood; 2018 Apr; 131(15):1743-1754. PubMed ID: 29348127
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of EZH2 Ameliorates Lupus-Like Disease in MRL/lpr Mice.
Rohraff DM; He Y; Farkash EA; Schonfeld M; Tsou PS; Sawalha AH
Arthritis Rheumatol; 2019 Oct; 71(10):1681-1690. PubMed ID: 31106974
[TBL] [Abstract][Full Text] [Related]
35. Genetic or pharmacologic blockade of enhancer of zeste homolog 2 inhibits the progression of peritoneal fibrosis.
Shi Y; Tao M; Wang Y; Zang X; Ma X; Qiu A; Zhuang S; Liu N
J Pathol; 2020 Jan; 250(1):79-94. PubMed ID: 31579944
[TBL] [Abstract][Full Text] [Related]
36. Blockade of Syk ameliorates the development of murine sclerodermatous chronic graft-versus-host disease.
Le Huu D; Kimura H; Date M; Hamaguchi Y; Hasegawa M; Hau KT; Fujimoto M; Takehara K; Matsushita T
J Dermatol Sci; 2014 Jun; 74(3):214-21. PubMed ID: 24679982
[TBL] [Abstract][Full Text] [Related]
37. Selective targeting of histone modification fails to prevent graft versus host disease after hematopoietic cell transplantation.
Alahmari B; Cooper M; Ziga E; Ritchey J; DiPersio JF; Choi J
PLoS One; 2018; 13(11):e0207609. PubMed ID: 30452487
[TBL] [Abstract][Full Text] [Related]
38. Donor-derived regulatory B cells are important for suppression of murine sclerodermatous chronic graft-versus-host disease.
Le Huu D; Matsushita T; Jin G; Hamaguchi Y; Hasegawa M; Takehara K; Tedder TF; Fujimoto M
Blood; 2013 Apr; 121(16):3274-83. PubMed ID: 23422748
[TBL] [Abstract][Full Text] [Related]
39. Changes in Immunosuppressive Treatment of Chronic Graft-versus-Host Disease: Comparison of 2 Surveys within Allogeneic Hematopoietic Stem Cell Transplant Centers in Germany, Austria, and Switzerland.
Wolff D; Hilgendorf I; Wagner-Drouet E; Jedlickova Z; Ayuk F; Zeiser R; Schäfer-Eckart K; Gerbitz A; Stadler M; Klein S; Middeke JM; Lawitschka A; Winkler J; Halter J; Holler E; Kobbe G; Stelljes M; Ditschkowski M; Greinix H
Biol Blood Marrow Transplant; 2019 Jul; 25(7):1450-1455. PubMed ID: 30876928
[TBL] [Abstract][Full Text] [Related]
40. Combinatorial inhibition of Tec kinases BTK and ITK is beneficial in ameliorating murine sclerodermatous chronic graft versus host disease.
Palaniyandi S; Strattan E; Kumari R; Mysinger M; Hakim N; Kesler MV; Apatira M; Bittencourt F; Wang L; Jia Z; Gururaja TL; Hill RJ; Hildebrandt GC
Bone Marrow Transplant; 2023 Aug; 58(8):924-935. PubMed ID: 37160943
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
